Johnson & Johnson eyes up to $3.4bn Ollin Biosciences deal

Johnson & Johnson eyes up to $3.4bn Ollin Biosciences deal
J&J targets $3.4B Ollin deal

Biotechnology dealmaking remains elevated this year as large drugmakers keep pursuing targeted acquisitions to expand their pipelines. Johnson & Johnson is poised to buy eye disease developer Ollin Biosciences for up to $3.4 billion, a move that would broaden its reach in retinal medicines.

Highlights

  • Johnson & Johnson is negotiating a potential acquisition of Ollin Biosciences for up to $3.4 billion, including $2.2 billion upfront and $1.2 billion in milestone payments.
  • The acquisition would grant J&J entry into the retinal disease treatment market, leveraging Ollin's OLN324 drug set for late-stage trials in wet AMD and diabetic macular oedema.
  • Biotech M&A remains robust with 46 $1 billion-plus deals totaling $131.5 billion in the first half of 2024, although activity has slowed to $44.8 billion in the second half.

Deal terms and strategic fit

As first reported by the Financial Times, Johnson & Johnson could announce an acquisition of privately held Ollin Biosciences as soon as Monday, according to people familiar with the matter.

The terms under discussion include $2.2 billion in upfront cash and another $1.2 billion tied to potential milestone payments, although the people cautioned that the talks could still collapse. J&J declined to comment, while Ollin did not respond to requests for comment.

Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing a medicine for two major causes of severe vision loss later in life. Its lead drug, OLN324, is set to enter late-stage trials for wet age-related macular degeneration and diabetic macular oedema, both of which can cause serious vision impairment.

An acquisition would give J&J a foothold in retinal disease treatments, an area where it has limited presence despite its large contact lens business. The company has already been active on acquisitions, agreeing a $1 billion deal for oncology developer Firefly Bio earlier this year and a $14.6 billion takeover of Intra-Cellular Therapies at the start of last year.

Biotech M&A momentum stays strong

The potential transaction comes as the pharmaceutical industry prepares to gather in London for the Jefferies healthcare summit this week, a key event for executives, investors and advisers. It also arrives during a record year for biotech sales, with 46 biotechs valued at more than $1 billion sold so far this year, surpassing the previous annual record of 35, according to Stifel.

After a strong first half, when $131.5 billion of biotech deals were agreed, activity has slowed in recent months. Transactions in the second half of the year total $44.8 billion so far.

Large pharmaceutical groups have continued to pursue eye disease assets in recent years, with companies including Merck and Bayer acquiring earlier-stage businesses. Regeneron's retinal treatment Eylea has been one of the sector's most successful blockbuster medicines, underscoring the commercial potential of the market.

Ollin raised $330 million earlier this year to fund its upcoming phase-three trials. Its backers also include TCGX, RA Capital and Monograph Capital, while J&J shares are up 38 per cent so far this year, giving the company a market capitalisation of nearly $688 billion at Friday's close.

In earlier coverage, we examined Canaccord’s UK wealth sale to Centerbridge and Mubadala for about £564 million.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.